Charcot Arthropathy — Neuroarthropathy

Charcot arthropathy (neuroarthropathy) is a progressive, destructive arthropathy of a joint or the foot and ankle that occurs in the setting of peripheral neuropathy. The loss of protective sensation leads to unrecognised repetitive micro-trauma and eventually catastrophic joint destruction, deformity, and instability. In the modern era, diabetes mellitus is the overwhelming cause, though any condition causing peripheral neuropathy can produce Charcot changes. The primary clinical challenge is early recognition — the acute Charcot foot is hot, swollen, and painful, and is easily mistaken for infection, gout, or cellulitis. Delayed diagnosis leads to severe deformity, instability, chronic ulceration, and ultimately amputation.

• Causes: diabetes mellitus (the most common — accounting for >90% of cases in the developed world); other causes — tabes dorsalis (syphilis — historically the classic cause; the `Charcot joint` was originally described by Jean-Martin Charcot in tabetic patients in 1868); syringomyelia (shoulder and elbow — `upper limb Charcot`); leprosy; alcoholic neuropathy; hereditary sensorimotor neuropathy (Charcot-Marie-Tooth); spinal cord injury
• Two theories of pathogenesis — neurotraumatic vs neurovascular: (1) Neurotraumatic theory (Volkmann and Virchow) — loss of protective sensation → unrecognised repetitive microtrauma to the joint → progressive bone and joint destruction; the neuropathy removes the pain protective reflex, allowing continued weight-bearing on damaged structures; (2) Neurovascular theory (Charcot) — autonomic neuropathy → sympathetic denervation → loss of vasomotor tone → arteriovenous shunting → hyperaemia and increased blood flow to bone → osteoclast activation → bone resorption and destruction; most authorities now accept that both mechanisms contribute — the neurovascular mechanism produces the initial bone resorption and the neurotraumatic mechanism causes subsequent structural collapse
• RANKL pathway: in diabetic Charcot, trauma triggers an inflammatory cascade; inflammatory cytokines (TNF-α, IL-1β, IL-6) upregulate RANKL (receptor activator of NF-κB ligand); RANKL activates osteoclasts via RANK on osteoclast precursors; unchecked osteoclast activity drives the bone destruction of acute Charcot; this is the target for bisphosphonate therapy (bisphosphonates inhibit osteoclast activity)

• Sanders-Frykberg anatomical patterns: Pattern I — forefoot (metatarsophalangeal + interphalangeal joints; least severe); Pattern II — tarsometatarsal joints (Lisfranc joint complex — the most common Charcot pattern in diabetes; produces the classic `rocker bottom` deformity as the midfoot collapses into plantarflexion); Pattern III — naviculocuneiform + calcaneocuboid joints (midtarsal); Pattern IV — ankle + subtalar joint (most severe; produces severe hindfoot instability); Pattern V — calcaneus (calcaneal fracture in Charcot — rare)

• The clinical challenge: acute Charcot arthropathy and diabetic foot osteomyelitis have almost identical clinical presentations — hot, red, swollen foot in a diabetic patient; both may have elevated inflammatory markers; distinguishing the two is critical because the management is opposite — Charcot requires offloading and protected weight-bearing whereas osteomyelitis requires debridement, antibiotics, and may require amputation; misdiagnosis leads to inappropriate treatment and catastrophic outcomes
• Clinical clues: Charcot foot — swelling and erythema resolves by 50% with elevation (vascular/inflammatory); intact skin (no ulcer or wound overlying the hot area); neuropathy present; osteomyelitis — swelling does NOT reduce with elevation; usually has a wound or ulcer overlying the infected bone; wound probe test (bone can be probed through the wound = high specificity for osteomyelitis); sinus tract to bone
• Investigations: plain X-ray (Charcot — fragmentation + subluxation; osteomyelitis — periosteal reaction + bone destruction at a specific site); MRI (the best investigation for distinguishing the two — Charcot: T2 high signal in subchondral bone at joint sites, diffuse marrow oedema; osteomyelitis: T2 high signal with cortical destruction, soft tissue abscess, sinus tract enhancement; however, osteomyelitis superimposed on Charcot is a real entity and MRI differentiation is not always possible); bone biopsy (definitive — confirms infection); leukocyte-labelled bone scan (WBC scan) has the highest specificity for osteomyelitis in the diabetic foot
• Temperature differential: a contact thermometer measuring the temperature difference between the involved and contralateral foot is the most practical tool for monitoring Charcot activity; >2°C difference = active Charcot; used to guide progress from acute TCC to CROW walker to custom footwear; the temperature differential normalises as the disease progresses to Stage III

• Surgical indications: surgery is reserved for Stage III (stable, consolidated) Charcot with deformity that cannot be accommodated in footwear, recurrent ulceration over a bony prominence that does not heal with offloading, and ankle/subtalar Charcot with instability that cannot be controlled orthetically; surgery in the acute stage (Stage 0/I) is associated with extremely high complication rates (non-union, infection, amputation) due to the active bone destruction — surgery should generally be deferred until the foot is quiescent (Stage III)
• Midfoot Charcot (Pattern II — Lisfranc collapse): the rocker bottom deformity is addressed by midfoot arthrodesis (Lisfranc/midfoot fusion) using intramedullary beaming (long-shaft screws placed from the hindfoot through the midfoot into the metatarsal shafts — `superbeam` technique); or traditional plate + screw arthrodesis; the goal is to create a stable, plantigrade foot that can be accommodated in custom footwear; exostectomy (excision of the bony prominence causing ulceration) is a simpler procedure for isolated pressure ulcers without global instability
• Hindfoot/ankle Charcot (Pattern IV): the most challenging; severe ankle and subtalar joint destruction creates a flail ankle with equinus and valgus deformity; tibiocalcaneal arthrodesis (fusion of the tibia directly to the calcaneum — bypassing the destroyed ankle and subtalar joints) using an intramedullary nail is the standard reconstruction; this is a major operation with significant complication rates (non-union 20–30%, infection, hardware failure, amputation); the alternative is a Charcot restraint orthotic walker (CROW) for the rest of the patient`s life if surgery is not feasible

• Charcot arthropathy: peripheral neuropathy (diabetes in >90% of modern cases) + repetitive micro-trauma + autonomic dysfunction → progressive joint destruction; originally described by Charcot in tabetic (syphilis) patients in 1868
• Two pathogenesis theories: neurotraumatic (loss of protective sensation → unrecognised trauma → destruction) + neurovascular (autonomic neuropathy → hyperaemia → osteoclast activation → bone resorption); both contribute; RANKL pathway drives osteoclast activation
• Eichenholtz Stage 0: hot swollen foot, normal X-ray, MRI oedema; THIS IS THE CRITICAL STAGE — offload immediately in TCC to prevent progression to fragmentation; the window to prevent deformity
• Charcot vs osteomyelitis: the critical distinction; Charcot — intact skin, swelling reduces with elevation; osteomyelitis — wound/ulcer, bone probe positive, swelling does NOT reduce; MRI + leukocyte bone scan for definitive distinction
• Temperature differential (>2°C): the monitoring tool for Charcot activity; normalisation guides progression from TCC to CROW walker to custom footwear
• Sanders-Frykberg Pattern II (Lisfranc collapse): the most common Charcot pattern in diabetes; tarsometatarsal joint destruction; `rocker bottom` deformity
• Pattern IV (ankle/subtalar): most severe; hindfoot instability; tibiocalcaneal intramedullary nail arthrodesis for surgical reconstruction; high complication rate (non-union ~20–30%)
• Total contact cast (TCC): the gold standard offloading device for Charcot; redistributes pressure across the entire plantar surface; reduces oedema; applied by trained personnel; weekly change initially; non-removable (prevents non-compliance)
• Surgery: defer until Stage III (quiescent, consolidated); acute stage surgery has catastrophic complication rates; midfoot — intramedullary beaming; hindfoot/ankle — tibiocalcaneal fusion
• Bisphosphonates (IV pamidronate/zoledronic acid): inhibit osteoclasts; reduce bone turnover markers; evidence limited but used as adjunct in acute Stage 0/I Charcot